HR+/HER2-low breast cancer is a significant subgroup of conventional HR+/HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR+/HER2-low breast cancer. The gene discussed is ERBB2; the disease is breast cancer.